The Potential for Targeting AVIL and Other Actin-Binding Proteins in Rhabdomyosarcoma.

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• Rhabdomyosarcoma (RMS) is a prevalent pediatric soft-tissue cancer with poor survival rates for high-risk patients.
• Current treatments lack targeted therapies, necessitating novel approaches.
• Actin-binding proteins, like advillin (AVIL), are crucial for cytoskeletal functions but challenging to target therapeutically.

Purpose of the Study:

• To investigate the role of advillin (AVIL) in rhabdomyosarcoma (RMS) tumorigenesis.
• To explore the therapeutic potential of targeting AVIL in RMS.
• To assess the feasibility of targeting oncogenic actin-binding proteins.

Main Methods:

• Analysis of AVIL expression in RMS cell lines, xenograft models, and patient samples.
• Induction of neoplastic transformation by AVIL overexpression in mesenchymal stem cells.
• Genetic modulation to reverse AVIL overexpression and its effects.

Main Results:

• AVIL is overexpressed across RMS subtypes (ARMS and ERMS) and models.
• AVIL overexpression drives in vitro and in vivo neoplastic transformation.
• Reversing AVIL overexpression mitigates tumor transformation.

Conclusions:

• AVIL plays a critical role in RMS initiation and maintenance.
• Targeting AVIL presents a promising, albeit challenging, therapeutic avenue for RMS.
• This research opens possibilities for targeting cancer-specific cytoskeletal vulnerabilities.